Back to mobile site

Mirum Pharmaceuticals (MIRM) PT Raised to $156 at Stifel on Clinical/Regulatory Wins

October 15, 2026 9:34 AM EDT Send to a Friend
Stifel analyst James Condulis raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $156.00 (from $136.00) while maintaining a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login